secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-08-28T12:30:17+00:00
Accession:  0001104659-26-102795
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea expands IP portfolio to 28 issued, 30 pending patents for oncology programs
--------------------------------------------------------------------------------

- Total portfolio now 28 issued and 30 pending patents across WEE1 and ATR inhibitor programs.
- WEE1 program: 2 pending US apps, 1 provisional, 2 granted non-US patents (Australia, Korea), 12 pending non-US; expiry 2047.
- ATR program: 4 granted US patents, 22 granted non-US, 13 pending non-US; granted expire 2035-2037, pending could extend to 2045.
- Lead WEE1 inhibitor APR-1051 in ACESOT-1051 Phase 1 trial for advanced solid tumors with gene alterations.
- ATRN-119 RP2D set at 1,100 mg once daily in 2025; study closed to focus on APR-1051, combo approaches considered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926102795/0001104659-26-102795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926102795/apre-20260828x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-102795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer